127 related articles for article (PubMed ID: 32446873)
1. Turning weakness into strength: Albumin nanoparticle-redirected amphotericin B biodistribution for reducing nephrotoxicity and enhancing antifungal activity.
Liu Y; Han Y; Fang T; Chen SM; Hu X; Song L; Shen H; Dong H; Jiang YY; Zou Z; Li Y; An MM
J Control Release; 2020 Aug; 324():657-668. PubMed ID: 32446873
[TBL] [Abstract][Full Text] [Related]
2. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R
J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532
[TBL] [Abstract][Full Text] [Related]
3. Preparation and In vitro Evaluation of Efficacy and Toxicity of Polysorbate 80-coated Bovine Serum Albumin Nanoparticles containing Amphotericin B.
Pedroso LS; Khalil NM; Mainardes RM
Curr Drug Deliv; 2018; 15(7):1055-1063. PubMed ID: 29629661
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of risk factors for liposomal amphotericin B-associated nephrotoxicity.
Yokota T; Yoshikawa N; Arimori K; Ikeda R
Pharmazie; 2020 Nov; 75(11):599-601. PubMed ID: 33239137
[TBL] [Abstract][Full Text] [Related]
6. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Brogden RN; Goa KL; Coukell AJ
Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
[TBL] [Abstract][Full Text] [Related]
8. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
9. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
10. Bovine Serum Albumin Nanoparticles Containing Amphotericin B: Characterization, Cytotoxicity and In Vitro Antifungal Evaluation.
Casa DM; Karam TK; Alves Ade C; Zgoda AA; Khalil NM; Mainardes RM
J Nanosci Nanotechnol; 2015 Dec; 15(12):10183-8. PubMed ID: 26682465
[TBL] [Abstract][Full Text] [Related]
11. Mixed micellar nanoparticle of amphotericin B and poly styrene-block-poly ethylene oxide reduces nephrotoxicity but retains antifungal activity.
Han K; Miah MA; Shanmugam S; Yong CS; Choi HG; Kim JA; Yoo BK
Arch Pharm Res; 2007 Oct; 30(10):1344-9. PubMed ID: 18038914
[TBL] [Abstract][Full Text] [Related]
12. Chitosan functionalized poly (ε-caprolactone) nanoparticles for amphotericin B delivery.
Vásquez Marcano RGDJ; Tominaga TT; Khalil NM; Pedroso LS; Mainardes RM
Carbohydr Polym; 2018 Dec; 202():345-354. PubMed ID: 30287009
[TBL] [Abstract][Full Text] [Related]
13. N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis.
Magalhães TFF; Costa MC; Holanda RA; Ferreira GF; Carvalho VSD; Freitas GJC; Ribeiro NQ; Emídio ECP; Carmo PHF; de Brito CB; de Souza DG; Rocha CEV; Paixão TA; de Resende-Stoianoff MA; Santos DA
Med Mycol; 2020 Aug; 58(6):835-844. PubMed ID: 31919505
[TBL] [Abstract][Full Text] [Related]
14. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
15. Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii.
Batista-Duharte A; Lastre M; Romeu B; Portuondo DL; Téllez-Martínez D; Manente FA; Pérez O; Carlos IZ
Int Immunopharmacol; 2016 Nov; 40():277-287. PubMed ID: 27639705
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B.
Wang Y; Ke X; Voo ZX; Yap SSL; Yang C; Gao S; Liu S; Venkataraman S; Obuobi SAO; Khara JS; Yang YY; Ee PLR
Acta Biomater; 2016 Dec; 46():211-220. PubMed ID: 27686042
[TBL] [Abstract][Full Text] [Related]
19. Renal impairment and amphotericin B formulations in patients with invasive fungal infections.
Saliba F; Dupont B
Med Mycol; 2008 Mar; 46(2):97-112. PubMed ID: 18324488
[TBL] [Abstract][Full Text] [Related]
20. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
